OSI, Genentech Slump on Avastin-Tarceva Miss

October 2008
Bioworld Week;10/13/2008, Vol. 16 Issue 41, p3
The article cites a study which shows that Avastin and Tarceva in combination failed in a Phase II trial to improve overall survival of patients with non-small-cell lung cancer (NSCLC). In notes that Avastin was marketed by Genentech Inc., while OSI Pharmaceuticals Inc. marketed Tarceva under a partnership with Genentech in the U.S. It is concluded that the outcome of trial known as BeTa Lung does not harm sales of the said drugs.


Related Articles

  • Tarceva trial fails.  // Long Island Business News (7/1993 to 5/2009);10/10/2008, Vol. 55 Issue 50, p12A 

    The article focuses on the failure of a clinical trial conducted by Genentech Inc. and OSI Pharmaceuticals Inc. on a combination of two cancer drugs to improve survival of patients with lung cancer in New York. According to the two companies, the trial was called BeTa Lung which has met its...

  • Lung Cancer Paradigms May Shift as New Data Emerge. Morrison, Trista // BioWorld Financial Watch;2/16/2009, Vol. 17 Issue 7, p1 

    The article discusses the emergence of new data regarding the use of biomarkers, studies of combination treatment regimens and progress with new targeted agents in lung cancer treatment. It states that the standard treatment of non-small-cell lung cancer (NSCLC), which is responsible for 90...

  • Tarceva Data Intensify Lung Cancer Competition.  // Bioworld Week;7/20/2009, Vol. 17 Issue 29, p3 

    The article reports that OSI Pharmaceuticals Inc., and partner Genentech Inc., have given a tough blow to their competitor Eli Lilly & Co. by announcing a drug for the treatment of lung cancer. As stated, the EGFR-inhibitor Tarceva (erlotinib) demonstrated a statistically significant overall...

  • Untitled.  // BioWorld Today;6/2/2009, Vol. 20 Issue 104, p13 

    The article reports on the results of the Phase III ATLAS study disclosed by South San Francisco, California-based Genentech Inc., U.S. Tarceva (erlotinib) partner of Melville, New York-based OSI Pharmaceuticals Inc. The study showed that advanced non-small cell lung cancer patients who received...

  • Other Cancers News Headlines March 15, 2004--April 14, 2004.  // PharmaWatch: Cancer;May 2004, Vol. 3 Issue 5, p17 

    Presents a roundup of cancer news headlines for the period of March 15, 2004, to April 14, 2004. OSI Pharmaceuticals Inc.'s initiation of a phase II study of the lung cancer drug Tarceva; Uncertainty surrounding SuperGen's Dacogen study; Effectiveness of Ariad's oncology product AP23464 in...

  • OSI Pharmaceuticals begins phase II study of lung cancer drug Tarceva.  // PharmaWatch: Cancer;May 2004, Vol. 3 Issue 5, p17 

    Reports that OSI Pharmaceuticals Inc. has initiated a phase II randomized study of monotherapy Tarceva versus standard chemotherapy of previously untreated non-small cell lung cancer patients with a poor performance status. Mechanism of action of the drug; Design of the study.

  • OSI, Genentech Slump on Avastin-Tarceva Miss. Young, Donna // BioWorld Today;10/7/2008, Vol. 19 Issue 195, p5 

    The reports on the decline in the shares of Genentech Inc. and OSI Pharmaceuticals Inc. on the news that their targeted therapies Avastin and Tarceva in combination failed in a Phase III trial to improve overall survival of patients with non-small-cell lung cancer (NSCLC). OSI's stock fell 14.3...

  • ELI LILLY & CO.  // MondayMorning;9/10/2012, Vol. 20 Issue 34, p1 

    The article reports that Eli Lilly & Co.'s drug regimen that included its Alimta therapy did not improve the survival of lung cancer patients in a late-stage clinical trial. According to the company, patients who were treated with a combination of Alimta, Avastin, and the chemotherapy drug...

  • Avastin-Tarceva combination fails in lung cancer. Jones, Dan // Nature Biotechnology;Feb2009, Vol. 27 Issue 2, p108 

    The article gives perspective on research of combination drug therapies used in oncology by first reporting findings regarding the combined use of Genetech's Avastin and OSI Pharmaceutical's Tarceva. As reported at the Chicago Multidisciplinary Symposium in Thoracic Oncology in November 2008,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics